Sign In
Buy CDNA
$38.37
-1.36 (-3.42%)
At Close: Jul 20, 2026
CareDx Names Ankur Dhingra as New Chief Financial Officer
04:05pm, Thursday, 11'th Mar 2021
SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clini
Like Guardant Health? You'll Love CareDx
08:17am, Wednesday, 03'rd Mar 2021
This under-the-radar diagnostics company is thriving yet reasonably priced.
CareDx, Inc. (CDNA) CEO Reginald Seeto on Q4 2020 Results - Earnings Call Transcript
10:38pm, Wednesday, 24'th Feb 2021
CareDx, Inc. (CDNA) CEO Reginald Seeto on Q4 2020 Results - Earnings Call Transcript
CareDx Reports Fourth Quarter and Full Year 2020 Results
04:01pm, Wednesday, 24'th Feb 2021
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinica
CareDx (CDNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
01:42pm, Wednesday, 17'th Feb 2021
CareDx (CDNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CareDx to Report Fourth Quarter and Full Year 2020 Financial Results
07:00am, Friday, 12'th Feb 2021
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinic
CareDx to to Participate in Upcoming BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
07:00am, Wednesday, 10'th Feb 2021
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinica
CareDx Showcases Cellular Transplantation and Therapy Portfolio at TCT
07:00am, Friday, 05'th Feb 2021
CareDx and Atara Biotherapeutics' AlloCell Partnership Highlighted in Poster Presentation at Upcoming TCT Meeting CareDx and Atara Biotherapeutics' AlloCell Partnership Highlighted in Poster Presentat
CareDx Announces Closing of Public Offering of Common Stock
04:28pm, Monday, 25'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinica
CareDx Announces Pricing of Public Offering of Common Stock
10:56pm, Wednesday, 20'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinica
CareDx Announces Proposed Public Offering of Common Stock
04:14pm, Tuesday, 19'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinica
CareDx Agrees to Acquire TransChart and Expands EMR Connectivity to Over 90 Centers
07:01am, Friday, 08'th Jan 2021
Acquisition will build on CareDx's digital capabilities and continue deepening the moat with transplant centers Acquisition will build on CareDx's digital capabilities and continue deepening the moat
CareDx Transplant Leadership Showcased at ASTS 2021
07:00am, Friday, 08'th Jan 2021
CareDx Shares Latest Clinical Data at the 21st Annual American Society of Transplant Surgeons Digital Winter Symposium CareDx Shares Latest Clinical Data at the 21st Annual American Society of Transpl
CareDx's AlloSeq HCT Wins Tender for French Stem Cell Transplant Patient Surveillance
07:00am, Monday, 04'th Jan 2021
CareDx wins a 2-year competitive tender with the French National Blood Service, Établissement Français du Sang CareDx wins a 2-year competitive tender with the French National Blood Service, Établi
CareDx: Stock To Achieve Significant Long-Term Growth
07:54am, Sunday, 03'rd Jan 2021
CareDx offers organ testing products that are non-invasive alternatives to more invasive traditional tests. The organ transplant market is expected to grow through 2027, creating a tailwind for CareDx
